Reduced work ability in cancer survivors

Problems with survivorship care in Europe

Underprovision and inequality of specialised cancer care

Regorafenib versus lomustine for relapsed glioblastoma

Reviewing LORELEI, mindACT and ExteNET trials in breast cancer

PACIFIC trial of durvalumab for stage III NSCLC

Questioning the role of CT-scan in NSCLC post-surgery follow-up

Osimertinib suitable for first line EGFRm lung cancer

FLAURA study of osimertinib versus TKI for 1st line NSCLC

Follow-up on the IFCT-0302 trial

PACIFIC trial of durvalumab for lung cancer

ESMO 2017: CDK4/6 inhibitors from a patient’s perspective